SUMMARY A double-blind study of pindolol eye drops 0-5% was carried out on 24 patients with primary open-angle glaucoma. Pressures were taken once weekly during three 3-week periods. In one of these periods placebo was given in both eyes, during another pindolol was given in one eye, and during another it was given in the other eye. A drop in pressure averaging 2-79% was found in eyes receiving pindolol compared with the period when they were receiving saline. Substantial placebo effects were found when in-trial pressures were compared with pretrial, but the placebo effects were avoided in the analysis of the pindolol effect. Blood pressure and pulse rates were not significantly affected. There was slight evidence of pindolol in one eye affecting the contralateral eye but little evidence of persistence of hypotensive effects after cessation of treatment.
The ocular hypotensive effect of pindolol has been described by various authors including Bonomi and Steindler' and S. E. Smith etal. 2 The study about to be described was an appraisal of the pressure-lowering effect of topical pindolol while patients with chronic glaucoma continued to take their usual medication. Thus the protocol was similar to that employed by R. Smith et al.3 in respect of timolol. The arrangements were, however, not identical in that a double placebo period was introduced which had not been employed in the prior study.
Patients and methods
Twenty-four patients with chronic primary openangle glaucoma were selected. They were already taking local medication but not acetazolamide. The majority were on pilocarpine plus guanethidine and adrenaline. They were asked if they were willing to try a new drug i.i addition to their existing treatment and their consent was obtained before entering them into the trial. The selection was limited to patients of 40 years or more, male or female, with a pulse rate of 61 or more and a blood pressure of at least 120/70 mmHg.
At an initial session the following data were
Correspondence to Mr Redmond Smith. recorded: name, age, sex, intraocular pressure in each eye, date and time of measurement, visual acuity, blood pressure, and pulse rate. Existing therapy was continued and the Pharmacy issued 2 extra identical bottles, one containing nor-mal saline and the other either normal saline or pindolol 0 5% (Moorfields formulation). Patients were instructed to instil one drop into the right eye from the bottle so marked and one into the left eye from the other bottle each morning and evening for one week, including the morning of the next visit. One week later the patients were reviewed and again on 2 more weekly visits. Then the therapy was altered for a further 3-week period and once more for a final 3-week period. All the examinations were carried out at about the same time of day in each patient.
The administration of pindolol or saline to one eye and saline to the other was arranged so that by the end of the trial each patient had had a 3-week period of drug in one eye and saline in the other, a period the other way round, and a period with saline in both eyes. It was arranged that one-third of the patients received double saline in the first, second, or last periods respectively. The trial was carried out doubleblind, and the Pharmacy held the code, which was not broken until the trial was completed.
FORMULATION
Both pindolol and placebo drops were prepared in 102 the Hospital Pharmacy and put up in identical packs. The only information given was the trial number of the patient, the treatment period, and the eye for which the bottle was to be used (right or left). The name and concentration of preservative was given (benzalkonium chloride was used in both active and placebo drops). Batch numbers were varied in each treatment period, though all drops were prepared at the same time, to prevent identification of the active drug by means of the batch number. 24-00 24-00 24-00 e = 549-00 Table 3 Comparison between pressures ofthe 8 eyes which Table 4 Comparison between pressures of the 8 eves which had double saline in the second period (SS2S) and the same had double saline in the third period (SS3S) and the same eyes when on pindolol (SS2P) eyes when on pindolol (SS3P) pressures 'on saline' (or 'on placebo') and pressures for left eyes. The mean pressures in these same eyes 'on pindolol,' pretrial pressures being totally during their later 3-week pindolol periods were 18-7 eliminated from the statistics. But the problem with and 19-87 respectively, a difference of 4-17 for right this approach is that cross-over and/or follow-on eyes and 3-54 for left, differences which appear to be effects may be operating. statistically significant. In order to eliminate cross-over or follow-on effects Ignoring any possible follow-on effects for the the 8 patients (16 eyes) who took saline in both eyes moment but avoiding cross-over effects we can also for the first 3-week period (the SS1 patients) may be study the 'double saline second' and 'double saline studied separately. Table 2 shows the findings. In third' groups. As in the 'double saline first' (or SS1) these patients the mean pressures during the 3 weeks group there are 8 patients and 16 eyes in each group. of placebo were 22-87 mmHg for right eyes and 23-41
AIMS AND OBJECTS
In the SS2 patients (Table 3 ) the mean pressures on The term 'follow-on' effect refers to the possibility of the effects of pindolol persisting for some time after administration had ceased. The mean pressures during the double placebo periods seem to get lower the later the period occurs in the trial. If we study the administration code (Table  6 ) it is apparent that in the SS2 group 8 of the 16 eyes concerned had received pindolol at some prior period. In order to test whether prior pindolol had affected the SS pressures it was found possible in the SS2 group to compare the pressures during the saline period of those eyes which had not and those eyes which had received prior pindolol-a comparison which could not be made either in the SSl or the SS3 group. Table 7 illustrates this analysis. SS2S eyes which had had prior pindolol showed a mean pressure of 20-16 mmHg, whereas eyes with no prior pindolol showed a mean pressure of 22-16-a difference of -2-0 mmHg. Each refers to 24 observations in only 8 eyes, and the difference might simply be due to On each of the 24 patients the blood pressure was taken 4 times when no pindolol was in use, that is, at the pretrial examination and at each of the exatninations during the double-saline period. The blood pressure was taken on 6 occasions while pindolol was in use, 3 times when in use in one eye and a further 3 times when it was in use in the other eye. Thus there were 96 readings taken with the patient off pindolol and 144 on pindolol (Table 11) . The means of the diastolic pressures 87-73 mmHg off pindolol and 88-77 mmHg on pindolol. The difference of -1-04 mmHg is not statistically significant.
SIDE EFFECTS
One patient complained of headaches lasting one week, but this was later found to have occurred during the double-placebo period. Another had a short period of conjunctival injection in the right eye after one week of pindolol, but the effect did not persist when the drug was continued. No other side effects were noted.
Discussion
In a previous study3 timolol was shown to lower intraocular pressure when added to existing medication. As in the present study the degree of lowering calculated by comparing pretrial pressure with pressure on timolol was greater than the in-trial comparison of the pressure when on saline compared with the pressure when on timolol.
Such a difference could be due either to a so-called placebo effect producing a lower in-trial saline pressure or to a cross-over effect from the contralateral eye on timolol. It was not feasible to disentangle the 2 possible effects in that study, so that the validity of the various comparisons made was weakened to some degree.
In the present study, however, the introduction of a double-placebo period has enabled us to identify with much more accuracy possible placebo effects, followon effects, and cross-over effects. As will have been seen in the account of the results, a placebo effect of 3 79 was found (Table 1) . There is no possibility of this being influenced by cross-over from the other eye, as the in-trial saline readings are all 'double saline' pressures. The existence of such a large placebo effect is of some interest and indicates the need for caution in assessing results in trials of this nature. Without the filtering out of the placebo effect (which we have achieved by ignoring pretrial readings) we would have been led into the trap of assuming a pindolol effect of 6-52 mmHg (Table 1) , more than half of which would in fact have been spunous.
The exact reasons for the placebo effect are not easy to determine. One possibility in this particular type of trial is that the pretrial pressure was taken at what the patient would have regarded as a routine visit, whereas later in-trial readings would be taken at what the patient would regard as a special visit. Under such conditions he or she might be more likely to have used their other prescribed treatment more conscientiously; in other words a clinical trial improves patient compliance.
Placebo effects having been obviated, tests for follow-on effects having shown a negative result (Table 8) , and cross-over effects having been avoided by comparing only double-saline pressures with pindolol, we are left with the result that pindolol undoubtedly lowered the pressure on average 2-79 mmHg when added to existing treatment.
Slowing of the pulse, effects on diastolic blood pressure, and other side effects were all negligible, so that it now seems justifiable to make further clinical trials of this drug.
Our thanks are due to Messrs Sandoz for supplies of pindolol for this trial.
